DHRS2 and infectious otitis media: A trial with an 11-valent predecessor of the currently licensed 10-valent pneumococcal conjugate vaccine (PCV10) that included Protein D from NTHi as a carrier protein, showed that the incidence of NTHi AOM decreased by 35%, suggesting protein-based vaccines may be effective against AOM [6].